News

Matthew Hertenstein is a psychologist at DePauw University, Greencastle, IN, who has studied the photographs of children and high school students and then determined what happened to them later in their lives. It turns out that people who smile more warmly in their photos when they are young will allegedly live longer and happier lives.

Refinements in the design of the Refocus Scleral Implants (Refocus Group) to treat presbyopia (and glaucoma) and in the surgical implantation technique have improved markedly over the year, making the devices easier to implant and the surgery shorter.

When managing staff, it is important to remember that employees are unique in their own way and want to be treated as individuals, so you should treat them as such.

Ocriplasmin receives J-Code

The Center for Medicare and Medicaid Services (CMS) has published the permanent Health-Care Common Procedure Coding System (HCPCS) code for ThromboGenics’ ocriplasmin (Jetrea), J7316.

According to a new study that examined the real-world usage of ranibizumab (Lucentis, Genentech) and aflibercept (Eylea, Regeneron), patients with wet age-related macular degeneration (AMD) required an equivalent number of injections over 6- and 12-month periods for both treatments.

The American Academy of Ophthalmology and the American Academy of Optometry have announced a joint initiative to work together to prepare and better support their members in delivering the highest quality eye care.

The FDA has issued a 510(k) clearance of a rapid, disposable test (InflammaDry, Rapid Pathogen Screening Inc. [RPS]) to aid in the diagnosis of dry eye disease for sale in the United States.

Researchers in the Cedars-Sinai Regenerative Medicine Institute have developed and tested a novel procedure to prepare human amniotic membrane for use as a scaffold for specialized stem cells used to treat some corneal diseases.

The United Kingdom's National Institute for Health and Care Excellence (NICE) published its final guidance for a sustained-release intravitreal implant (Iluvien), clearing the path to patient availability through the National Health Service (NHS).

Chronic pain can occur after refractive surgery, but it also can occur in patients with non-surgical ocular disease. It is important to distinguish both the causes and the manifestations of pain before one can successfully treat it, according to Todd P. Margolis, MD, PhD.

Bayer HealthCare of Leverkusen, Germany, has entered into an exclusive collaboration with Inception Sciences Inc. of San Diego and Versant Ventures of San Francisco to develop treatment options for patients with retinal diseases, such as wet age-related macular degeneration (AMD) and geographic atrophy (GA).

Throughout 2013, there were several studies done that showed various new technologies and advancements have not only shown better refractive outcomes in cataract surgery, but could continue benefiting the outcomes in the future.

While US cataract surgeons still have limited access to pseudophakic correction technology, there were several premium IOLs made available this year that offer toric correction, an important step forward.

The Japanese Ministry of Health, Labour, and Welfare has approved Regeneron Pharmaceuticals Inc.’s aflibercept (Eylea) injection for the treatment of macular edema following central retinal vein occlusion (CRVO).

A careful history taking-with special attention to risk factors-may aid ophthalmologists in the prevention of diplopia after surgical procedures, said Anya Trumler, MD.

In New Orleans, the theme song “The Saints Go Marching In,” sings the famous line, “I want to be in that Number.” The American Academy of Ophthalmology is hoping that thousands of its members will want to be in that number too-the Intelligent Research in Sight (IRIS) Registry, formally introduced on Sunday.

Before Paul Sternberg Jr., MD, steps aside from his role as the American Academy of Ophthalmology’s president, he said he does not look back to recount his time in the office. Instead, he addressed the future.